A treatment and/or preventive agent for prostatic hypertrophy includes a compound having an antagonistic effect to an angiotensin II receptor or a pharmaceutically acceptable salt or a prodrug thereof as an active ingredient wherein said compound having an antagonistic effect to an angiotensin II receptor is one or more compounds selected from the group consisting of losartan potassium losartan candesartan candesartan cilexetil balsartan eprosartan zolasartan telmisartan irbesartan tasosartan ol...

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE 1)UN ANTAGONISTA O BLOQUEADOR DEL RECEPTOR DE ANGIOTENSINA II COMO VALSARTAN LOSARTAN CANDESARTAN EPROSARTAN IRBESARTAN OLMESARTAN TASOSARTAN TELMISARTAN; 2a)UN POTENCIADOR DE LA SECRECION DE INSULINA COMO TOLBUTAMIDA CLORPROPAMIDA TOLAZAMIDA ACETOHEXAMIDA GLICOPIRAMIDA GLIBENCLAMIDA GLICLAZIDA 1-BUTIL-3-METANILILUREA CARBUTAMIDA GLIBONURIDA GLIPIZIDA GLIQUIDONA GLISOXEPIDA GLIBUTIAZOL GLIBUZOL GLIHEXAMIDA GLIMIDINA GLIPINAMIDA ENBUTAMIDA T...